Effect of lipid modification on peripheral arterial dis*
Effect of lipid modification on peripheral arterial dis*
批准号:
7120171
负责人:
ALAN B. LUMSDEN
金额:
$85.98万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-09-22 至 2008-06-30
关键词:
aerobic exerciseangiocardioultrasonographyantihypercholesterolemic agentartery occlusionatherosclerosisblood lipoproteinblood lipoprotein metabolismblood testsblood vessel prosthesiscardiovascular disorder chemotherapycardiovascular disorder preventionclaudicationclinical researchclinical trialscombination chemotherapyhuman subjecthuman therapy evaluationinflammationintraluminal angioplastylongitudinal human studymagnetic resonance imagingpatient oriented researchperipheral blood vessel disorderrestenosisthrombosistransforming growth factors
中文摘要
描述(由申请方提供):积极脂质修饰对预防下肢动脉粥样硬化和再狭窄进展的获益尚不清楚。由于缺乏对血管病变病理学的定量测量,这一领域受到严重阻碍。手术干预后再狭窄的完整自然史尚不清楚。我们将联合收割机结合我们的专业知识和资源在贝勒医学院在一个多学科的方法来解决这些重要的问题。我们假设,积极的血脂调节方案将通过减少血栓形成和炎症来抑制股动脉粥样硬化的进展,并降低血管内支架植入术后股动脉再狭窄的发生率。我们将招募共120例单腿症状性股动脉闭塞性疾病患者。这些患者将用血管内支架术治疗,并随机分为两组:1)标准医疗护理和2)增加HDL(> 40 mg/dl)并降低LDL(<80 mg/dl)和TG(<50 mg/dl)的积极脂质修饰疗法。我们将对这些患者进行为期两年的随访。我们的具体目标是:1)确定侵袭性脂质修饰对动脉粥样硬化进展和股动脉再狭窄的影响。最近,我们采用高分辨率磁共振成像(MRI)研究肢体血管病变,包括病变大小,成分和形态。该技术将用于检查植入支架的股动脉的支架内再狭窄和对侧股动脉的动脉粥样硬化进展或消退。2)确定积极的血脂调节方案对股动脉血管成形术和/或支架植入术后临床适用的血流动力学测量值以及减少全身性重大心血管事件的影响。Baylor的大量临床容量和出色的血管内治疗专业知识将使我们能够评价临床结局,包括踝臂指数(ABI)、步行距离、绝对跛行和严重PAD人群的多普勒超声。3)。研究侵袭性三联药物治疗对脂蛋白、炎症的影响,以及与PAD进展、再狭窄和临床事件的关系。LDL、HDL、TG、Lp(a)、颗粒大小和数量、hsCRP、TNF α、IL-8、MCP-1、sP-选择素、s-ICAM-1、s-VCAM-1和sCD 40 L的测定将允许对PAD进展和临床事件的机制性了解。4)。研究侵袭性三联药物治疗对血栓形成的影响,以及与PAD进展、再狭窄和临床事件的关系。这些研究与临床结局和定量股骨MR图像的关联将允许对PAD进展和临床事件的机制性见解。这项研究将提供一种新的策略,以延缓或预防动脉粥样硬化和动脉血运重建术后再狭窄的进展。重要的是,我们的MRI研究将首次提供有关血管病变的定量数据。最后,这些研究将推进我们对与侵袭性脂质修饰相关的炎症和血栓形成的分子机制的理解。
英文摘要
DESCRIPTION (provided by applicant): The benefit of aggressive lipid modification on the prevention of progression of atherosclerosis and restenosis in the lower extremity is unknown. This field is severely hampered by the lack of quantitative measurement of vascular lesion pathology. Complete natural history of restenosis following surgical intervention is not clear. We will combine our expertise and resources at Baylor College of Medicine in a multidisciplinary approach to address these important questions. We hypothesize that an aggressive regimen of serum lipid modification will inhibit the progression of atherosclerosis in femoral arteries and reduce the incidence of restenosis of femoral arteries following endovascular stenting by decreasing thrombosis and inflammation. We will recruit a total of 120 patients with symptomatic femoral artery occlusive disease in one leg. These patients will be treated with endovascular stenting, and randomized into two groups: 1) standard medical care and 2) aggressive lipid modification therapy which increases HDL (>40mg/dl) and decreases LDL (<80 mg/dl) and TG (cl50 mg/dl). We will follow these patients for 2 years. Our Specific Aims are to: 1) Determine the effect of aggressive lipid modification on progression of atherosclerosis and restenosis of femoral arteries. Recently, we have adapted high resolution magnetic resonance imaging (MRI) to study extremity vascular pathology including lesion size, composition, and morphology. This technology will be used to examine both the stented femoral artery for in-stent restenosis and the contralateral femoral artery for atherosclerosis progression or regression. 2) Determine the effects of an aggressive regimen of serum lipid modification on the clinically applicable hemodynamic measurements following femoral artery angioplasty and/or stenting and on the reduction of systemic major cardiovascular events. Large clinical volume and excellent endovascular therapy expertise at Baylor will enable us to evaluate the clinical outcomes, including ankle brachial index (ABI), walking distance, absolute claudication, and duplex ultrasound in a population with significant PAD. 3). Investigate effects of aggressive triple-drug therapy on lipoproteins, inflammation, and relationship to PAD progression, restenosis, and clinical events. Assays of LDL, HDL, TG, Lp(a), particle size and number, hsCRP, TNFalpha, IL-8, MCP-1, sP-selectin, s-ICAM-1, s-VCAM-1, and sCD40L will permit mechanistic insights into PAD progression and clinical events. 4). Investigate the effects of aggressive triple-drug therapy on thrombosis, and relationship to PAD progression, restenosis and clinical events. Association of these studies with clinical outcomes and quantitative femoral MR images will permit mechanistic insights into PAD progression and clinical events. This study will provide a novel strategy to retarding or preventing progression of atherosclerosis and restenosis following arterial revascularization procedures. Importantly, our MRI studies will, for the first time, provide quantitative data on the vascular lesions. Finally, these studies will advance our understanding of the molecular mechanisms of inflammation and thrombosis associated with aggressive lipid modification.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Effect of lipid modification on peripheral arterial dis*
-
批准号:6951747
-
项目类别:
-
资助金额:$2.6万
-
财政年份:2003
-
负责人:ALAN B. LUMSDEN
-
依托单位:
Effect of lipid modification on peripheral arterial dis*
-
批准号:6943956
-
项目类别:
-
资助金额:$88.6万
-
财政年份:2003
-
负责人:ALAN B. LUMSDEN
-
依托单位:
Effect of lipid modification on peripheral arterial dis*
-
批准号:6803030
-
项目类别:
-
资助金额:$89.4万
-
财政年份:2003
-
负责人:ALAN B. LUMSDEN
-
依托单位:
Effect of lipid modification on PAD
-
批准号:6732445
-
项目类别:
-
资助金额:$88.65万
-
财政年份:2003
-
负责人:ALAN B. LUMSDEN
-
依托单位:
海外基金